DrugsControl Media Services
DrugsControl.org

News Detail

US FDA approves Mesoblast's first-of-its-kind cell therapy (24-12-2024)

Maryland, 23 Dec 2024: An FDA advisory panel vote of 9-1 to recommend the approval of Mesoblast Limited’s graft versus host disease (GVHD) cell therapy was a cruel tease for the Australian company.

 

More than four years later—and after two r......
View Details

Source : Fierce Pharma
Mesoblast FDA approval graft-versus-host disease cell therapy allogeneic cell therapy Pharma drugscontrol Ryoncil

Related News